Integromics Appoints Dr. Michael J. McManus as President & CEO
Integromics announced that it has selected Dr. Michael J. McManus as President & CEO. Dr. McManus will lead the company’s efforts to expand in the world market, with a particular focus on proteomics and on further developing Integromics’ activity in the U.S. and Asian markets.
Dr. McManus, 52, has over 25 years of scientific software and business experience, including operational management, business development, strategic planning, research and development, product marketing and product management expertise. His scientific background spans chemistry (including synthetic organic, computational, cheminformatics, and polymer chemistry sub-disciplines), bioinformatics, data mining and visualization. Dr. McManus received his Ph.D. in synthetic organic chemistry from the Massachusetts Institute of Technology. He received his B.S. in chemistry, summa cum laude, from the University of Massachusetts, Amherst.
Prior to joining Integromics, Dr. McManus led GenomeQuest’s corporate marketing, strategic alliances, product marketing and product development efforts. Before joining GenomeQuest, Dr. McManus served as Vice President of Business Development for the BioSciences Group of Fujitsu Computer Systems, where he set up and initiated the Group's U.S. operations and as Executive VP and COO of AnVil Informatics, Inc. Prior to AnVil, he served as Vice President of Marketing and Business Development at CambridgeSoft Corporation.
Topics
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Bringing cancer medication safely to its destination
Apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy - New manufacturing capacity established in Ottobrunn near Munich
New genes implicated in high blood pressure

Start-up ViGeneron announces research collaboration with Daiichi Sankyo - Evaluate vgAAV for novel ophthalmic gene therapy
Hypocapnia
Mohs_surgery

Tracking down the tiniest of forces: how T cells detect invaders - T cells use their antigen receptors like sticky fingers - a research team was able to observe them doing so
